A Phase 1 interventional study of Continuous theta burst stimulation (cTBS) and Intermittent theta burst stimulation (iTBS) in Alcohol Use Disorder, sponsored by Indiana University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Indiana University · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Alcoholism by Indiana University — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Indiana University.
Among the 12 studies in Alcoholism by Indiana University, this one is the 7th largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 1, and was the 12th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →4 of the 12 studies in Alcoholism by Indiana University are open now, in 1 country. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18–60
Indiana University · Sites in United States
Ages 21–35 · Healthy volunteers
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 77 across the 12 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
2 of the studies in Alcoholism by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03827460Indiana UniversitySex Differences in the Response to Abstinence From Alcohol. | 2027-02-28 |
| NCT06302413Indiana UniversityEnhancing Prospective Thinking in Early Recovery (HOME) | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Alcoholism by Indiana University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.
Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.
rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.
Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.
Other: Continuous theta burst stimulation (cTBS) · Other: Intermittent theta burst stimulation (iTBS) · Other: Sham TBS · Drug: IV alcohol solution
On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.
Other: Continuous theta burst stimulation (cTBS) · Other: Intermittent theta burst stimulation (iTBS) · Other: Sham TBS · Drug: IV alcohol solution
cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.
iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.
Sham TBS duplicates the peripheral sensations of TBS without neurostimulation
Sterile alcohol is mixed with USP saline to a concentration of 6%
Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.
During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast \[Flavor \> Water\] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in cue-induced craving after TBS.
In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.
During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in impulsivity assessed using a delay discounting task after TBS.
Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in pDMN BOLD responses during a delay discounting task after TBS.
BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in pDMN functional connectivity during alcohol tasting after TBS treatment.
In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and salience network after TBS.
The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in within-DMN functional connectivity during a delay discounting task after TBS.
During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and cognitive control areas after TBS.
Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting.
Time frame: 3 single day laboratory sessions scheduled 7-14 days apart
Plan to share: Yes — We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.
Supporting information: Study protocol, Informed consent form
Time frame: After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,
Access criteria: On request to the PIs
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.
Of 63 non-industry phase 1 interventional studies under Alcoholism, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 53 months is above that.
Counting every sponsor, half of 75 studies reached it within 28 months; a quarter within 19 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.